Skip to main content
HairCited

미녹시딜 관련 여성형 탈모

A

총 28,815명의 참여자를 대상으로 한 67건의 연구(메타분석 4건, RCT 11건)에 근거합니다. 67건 중 53건의 연구에서 긍정적인 효과가 나타났습니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

결론

Research strongly suggests that minoxidil may help women with female pattern hair loss regain hair density, supported by numerous high-quality clinical trials.

  • 67 studies including 11 RCTs and 4 meta-analyses specifically in women
  • 79% of studies report positive effects on hair growth
  • Low-dose oral minoxidil is emerging as a well-tolerated alternative to topical application
  • Combination with other ingredients like spironolactone may enhance results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: women with androgenetic alopecia (female pattern hair loss)

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs: None Outcome: consensus recommendations for managing pattern hair loss 효과: None None

대상 집단: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

review
Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current …
Dose: varies by agent and study vs: Placebo 효과: variable; oral antiandrogens demonstrate some efficacy; topical antiandrogens possibly fewer systemi None
narrative review
Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions.
Dose: None vs: Placebo 효과: None None
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo 효과: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 효과: None None

Key Statistics

111

연구

37800

참여자

Positive

A

등급

Referenced Papers

Australian prescriber 2025 2 인용
Annals of dermatology 2025
SAGE open medical … 2024 3 인용
Drugs 2023 221 인용
Anais brasileiros de … 2023 29 인용
Journal of cosmetic … 2023 3 인용
The Journal of … 2022 170 인용
Faculty reviews 2022 44 인용
Journal of cosmetic … 2022 7 인용
Journal of the … 2021 42 인용
American journal of … 2020 127 인용
International journal of … 2020 58 인용
Indian dermatology online … 2020 31 인용
Actas dermo-sifiliograficas 2019 5 인용
Australian journal of … 2018 8 인용
JAMA dermatology 2017 121 인용
The Cochrane database … 2016 18 인용
World journal of … 2015 62 인용
Seminars in cutaneous … 2015 20 인용
Clinical obstetrics and … 2015 9 인용
Current problems in … 2015 8 인용
Skin therapy letter 2014 29 인용
Dermatologic clinics 2013 78 인용
International journal of … 2013 61 인용
Indian journal of … 2013 16 인용
International journal of … 2013
The Cochrane database … 2012 15 인용
Skinmed 2012 5 인용
Seminars in cutaneous … 2009 4 인용
American family physician 2009
Journal of the … 2008 290 인용
Clinical interventions in … 2007
Duodecim; laaketieteellinen aikakauskirja 2006
The British journal … 2005 205 인용
The journal of … 2003 102 인용
Clinical and experimental … 2002 61 인용
Therapeutische Umschau. Revue … 2002 4 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

topical:
2-5% solution, twice daily

상한량: 5% topical solution

연구에서 사용된 용량

용량 기간 효과 N
None -- Neutral --
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
varies by agent and study -- Positive --
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Spironolactone 100 mg once daily 24 weeks Positive 48
None -- Positive --

권장 복용 시간: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

보고된 부작용

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

알려진 상호작용

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

일일 최대 섭취 허용량: 5% topical solution

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 미녹시딜 help with 여성형 탈모?
Based on 111 studies with 37,800 participants, there is strong evidence from multiple clinical trials that 미녹시딜 may support 여성형 탈모 management. Our evidence grade is A (Strong Evidence).
How much 미녹시딜 should I take for 여성형 탈모?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 미녹시딜?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 미녹시딜 and 여성형 탈모?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 111 peer-reviewed studies with 37,800 total participants. The overall direction of effect is positive.

Related Evidence

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.